These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11978936)

  • 1. Impact of thalassemia major on patients and their families.
    Caro JJ; Ward A; Green TC; Huybrechts K; Arana A; Wait S; Eleftheriou A
    Acta Haematol; 2002; 107(3):150-7. PubMed ID: 11978936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use.
    Ward A; Caro JJ; Green TC; Huybrechts K; Arana A; Wait S; Eleftheriou A
    BMC Clin Pharmacol; 2002 Apr; 2():3. PubMed ID: 12015817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal abnormalities in β-thalassemia major.
    Bhoiwala DL; Dunaief JL
    Surv Ophthalmol; 2016; 61(1):33-50. PubMed ID: 26325202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
    Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
    Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
    Farmaki K; Tzoumari I; Pappa C
    Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B
    Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
    Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
    Kuo HT; Tsai MY; Peng CT; Wu KH
    Hemoglobin; 2006; 30(2):291-9. PubMed ID: 16798654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and complications in thalassemia.
    Borgna-Pignatti C; Cappellini MD; De Stefano P; Del Vecchio GC; Forni GL; Gamberini MR; Ghilardi R; Origa R; Piga A; Romeo MA; Zhao H; Cnaan A
    Ann N Y Acad Sci; 2005; 1054():40-7. PubMed ID: 16339650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
    Kuo HT; Peng CT; Tsai MY
    Hemoglobin; 2006; 30(2):301-9. PubMed ID: 16798655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major.
    Prati D
    Vox Sang; 2000; 79(3):129-37. PubMed ID: 11111230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience).
    Mokhtar GM; Gadallah M; El Sherif NH; Ali HT
    Pediatr Hematol Oncol; 2013 Mar; 30(2):93-103. PubMed ID: 23301991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH; Chang JS; Tsai CH; Peng CT
    Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine complications in patients with Thalassaemia Major.
    Toumba M; Sergis A; Kanaris C; Skordis N
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.